Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    Molecular and Genetic Characterization of Inborn Errors of Immunity

    By Global Biodefense StaffDecember 4, 2021
    Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

    These inborn errors of immunity result largely from inherited genetic defects that perturb immune regulation or function; they are often severe in nature; and are characterized by highly diverse phenotypes such as infection, autoimmunity, auto-inflammation, allergy, and malignancy.

    Genomic analysis and experimental validation of genetic variants have been instrumental in the identification of numerous inborn errors of immunity/primary immunodeficiencies to date. More than 400 inborn errors of immunity have been identified in both coding and non-coding regions of the genome, as noted in the “Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee“.

    The National Institute of Allergy and Infectious Diseases (NIAID) is supporting research to enable not only the molecular characterization of numerous known and novel inborn errors of immunity but, importantly, also reveal defects in immunoregulatory pathways responsible for the disease phenotype.

    In silico prediction models suggest that mutations in more than 3000 coding regions may cause unrecognized inborn errors of immunity, while numerous mutations in non-coding regions also are expected to cause disease, underlining the public health significance in understanding the genetic basis of primary immunodeficiency disorders and reinforcing the notion that hundreds to thousands of these disorders remain unidentified. Furthermore, since these disorders are characterized by a high degree of phenotypic heterogeneity, understanding their genetic basis is essential for appropriate diagnosis, prognosis, and treatment.

    Research areas supported by this NIAID grant program include the experimental validation and immunological characterization of:

    • Single nucleotide variants (inherited or de novo) in coding or non-coding regions of the genome that cause inborn errors of immunity;
    • Insertions or deletions (indels) in coding or non-coding regions of the genome that cause inborn errors of immunity;
    • Digenic/polygenic mutations that cause inborn errors of immunity;
    • Structural variations (large insertions or deletions, translocations, inversions, or copy-number variations) that cause inborn errors of immunity.

    When submitting applications, use of relevant cell types isolated from the patients and appropriate controls (e.g., unaffected family members, healthy subjects of the same ethnic origin etc.) are strongly encouraged for the delineation of the functional consequences of the mutations under investigation. If animal models are used to elucidate the mechanism of disease, a clear correlation between human and animal disease phenotypes should be established. In all cases, preliminary data should demonstrate that the genotype/phenotype correlation recapitulates the patient’s clinical disease.

    State-of-the-art technologies and approaches (e.g., iPSC technology, CRISPR/Cas9 gene editing, multi-omics such as transcriptomics, proteomics, epigenetics etc.) are also strongly encouraged.

    Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity. National Institute of Allergy and Infectious Diseases (NIAID). PA-20-185 – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed); PA-20-195 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed). This notice applies to due dates on or after February 5, 2022, and subsequent receipt dates through January 7, 2025.

    Editor Pick Immune Response Opportunities Request for Proposals
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleHow Well Do Covid Vaccines Hold Up Over Time? Macaque Study Shows Decline in Lung Protection
    Next Article Capturing Hidden Aspects of Epidemics Using Phylodynamics

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy